Dr. Sanober Kable, MD

Dr. Kable practices at Premier Pulmonary Critical Care and Sleep Medicine, PA in Denison, Texas.

Dr. Kable's NPI, 1295876399, was assigned on February 9, 2007. Dr. Kable graduated from Dow University of Health Sciences in 2001. Dr. Kable holds Texas license N3527.

Dr. Kable's primary practice is Premier Pulmonary Critical Care and Sleep Medicine, PA, at 5012 S Us-75, Denison, TX 75020 in Grayson County. The practice phone is (903) 465-5012.

Dr. Kable's primary practice is Premier Pulmonary Critical Care and Sleep Medicine, PA in Denison, Texas. Dr. Kable is also affiliated with Texoma Medical Center. The medical group on file is Premier Pulmonary Critical Care & Sleep Medicine. Dmand AI also links Dr. Kable to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kable practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Kable's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Kable is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kable's licenses on file in 4 states: Texas, Oklahoma, Michigan and Illinois.

Dmand AI lists asthma, bronchitis, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, chronic sinusitis, hypersomnia, lung resection and pleural effusion among the conditions Dr. Kable treats.

CMS data shows 54,277 Medicare services from Dr. Kable across 27 procedure codes in 2024, for 1,373 Medicare patients. Medicare paid $1,571,334 for them.

CMS counts 1,373 Medicare patients who saw Dr. Kable in 2024. The largest group is 65 to 74, with 646 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kable's median patient age at 71, with 59% women.

In 2024, Dr. Kable wrote 5,852 Medicare Part D claims for 1,346 patients. 54% of them were for generic drugs. CMS names the drug for 5,528 of them, across 62 drugs with 11 or more claims each, at $10,098,812 in total drug cost. In 2023, CMS named 6,640 claims across 72 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 46 out of 100 for Dr. Kable for performance year 2024, reported individually. Dr. Kable accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Kable to 1 clinical trial. Conditions studied include Pulmonary Arterial Hypertension and Hypertension, Pulmonary. Open Payments lists research payments to Dr. Kable that name 1 trial.

CMS Open Payments shows 2,492 general payments to Dr. Kable from 68 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. GlaxoSmithKline, LLC. paid the most, $83,358. It also lists 9 research payments totaling $70,830 from 2016 to 2019, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Kable, most recently President of Grayson County Medical Society in 2019.

Dr. Kable graduated from Dow University of Health Sciences in 2001. Dr. Kable is a member of AASM, ACCP and ATS.

Dr. Kable is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.